Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2701
LeMaitre Vascular
LMAT
$1.87B
| $2.64M | ﹤0.01% |
32,558
+2,560
| +9% | +$220K |
|
2702
RUM Group Inc
RUM
$3.74B
| $2.64M | ﹤0.01% |
417,454
+267,177
| +178% | +$1.83M |
|
2703
PUT
Rigetti Computing
RGTI
$6.21B
| $2.64M | ﹤0.01% |
119,000
+117,100
| +6,163% | +$3.82M |
|
2704
Tower Semiconductor
TSEM
$28.6B
| $2.63M | ﹤0.01% |
22,416
+13,471
| +151% | +$1.3M |
|
|
PVLA
2705
Palvella Therapeutics
PVLA
$2.23B
| $2.63M | ﹤0.01% |
25,136
+15,360
| +157% | +$1.31M |
|
2706
Sally Beauty Holdings
SBH
$1.55B
| $2.63M | ﹤0.01% |
184,430
-89,996
| -33% | -$1.36M |
|
2707
Lakeland Financial Corp
LKFN
$1.55B
| $2.63M | ﹤0.01% |
46,054
+8,634
| +23% | +$513K |
|
2708
Diebold Nixdorf
DBD
$2.45B
| $2.62M | ﹤0.01% |
38,572
+2,307
| +6% | +$144K |
|
2709
QuinStreet
QNST
$1.19B
| $2.61M | ﹤0.01% |
181,872
+7,908
| +5% | +$114K |
|
2710
Winmark
WINA
$1.26B
| $2.61M | ﹤0.01% |
6,447
+414
| +7% | +$177K |
|
2711
TripAdvisor
TRIP
$1.26B
| $2.61M | ﹤0.01% |
179,259
-159,761
| -47% | -$2.43M |
|
2712
Array Technologies
ARRY
$796M
| $2.61M | ﹤0.01% |
282,903
-248,189
| -47% | -$2.13M |
|
|
STEL
2713
DELISTED
Stellar Bancorp
STEL
| $2.61M | ﹤0.01% |
84,273
+14,717
| +21% | +$452K |
|
|
AAMI
2714
Acadian Asset Management
AAMI
$3.31B
| $2.61M | ﹤0.01% |
55,444
-2,008
| -3% | -$92.5K |
|
2715
UFP Technologies
UFPT
$2.48B
| $2.61M | ﹤0.01% |
11,735
+957
| +9% | +$205K |
|
2716
ArriVent BioPharma
AVBP
$1.47B
| $2.6M | ﹤0.01% |
129,173
-762
| -0.6% | -$15.9K |
|
|
RAPT
2717
DELISTED
RAPT Therapeutics
RAPT
| $2.6M | ﹤0.01% |
76,659
+76,564
| +80,594% | +$2.38M |
|
|
AUGO
2718
Aura Minerals Inc
AUGO
$6.5B
| $2.59M | ﹤0.01% |
+51,417
| New | +$2.02M |
|
2719
LegalZoom.com
LZ
$930M
| $2.59M | ﹤0.01% |
260,977
+83,635
| +47% | +$829K |
|
|
JKS
2720
JinkoSolar
JKS
$860M
| $2.59M | ﹤0.01% |
100,199
+71,278
| +246% | +$1.82M |
|
2721
Sylvamo
SLVM
$1.53B
| $2.58M | ﹤0.01% |
53,633
+3,683
| +7% | +$168K |
|
|
LGN
2722
Legence Corp
LGN
$4.86B
| $2.58M | ﹤0.01% |
59,933
+38,573
| +181% | +$1.52M |
|
2723
Harmonic Inc
HLIT
$1.42B
| $2.58M | ﹤0.01% |
260,804
+21,795
| +9% | +$220K |
|
2724
PUT
Dow Inc
DOW
$21.9B
| $2.57M | ﹤0.01% |
110,000
| – | – |
|
2725
EyePoint Inc
EYPT
$1.16B
| $2.57M | ﹤0.01% |
140,726
+37,023
| +36% | +$525K |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.